NCT06246552: An ongoing trial by Jetema USA Inc.
This trial is ongoing. It must report results 5 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06246552 |
|---|---|
| Title | Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Phase 2 Study of the Safety and Efficacy of JTM201 (Botulinum Toxin Type A) to Treat Moderate or Severe Glabellar Lines |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 26, 2024 |
| Completion date | June 5, 2025 |
| Required reporting date | June 5, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |